# RBC Capital

Type: Company (RY)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/rbc-capital
Canonical HTML page: https://getfinancebrief.com/entity/rbc-capital

## Timeline

- **2026-03-03**: TD Cowen Conference — AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
- **2026-02-26**: DOJ Legal Support — The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
- **2026-02-25**: RBC Coverage Launch — RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
- **2023-01-31**: Humira Exclusivity Ends — The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.

## Recent coverage (3 stories)

### UiPath's 46.3% August Rally: Sector Bet, Then Earnings Reality
2026-09-06 01:48:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

UiPath shares jumped 46.3% in August as enterprise software rebounded from AI-disruption fears and RBC Capital lifted price targets. The move preceded a fiscal Q2 report that fell short of elevated hopes, showing how much of the gain was sector sentiment rather than stock-specific news.
Full story: https://getfinancebrief.com/story/uipath-august-rally-finance

### RBC Bullish on Eli Lilly's Retatrutide Despite Mixed Trial Data
2026-03-20 05:29:58 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
Full story: https://getfinancebrief.com/story/rbc-capital-eli-lilly-retatrutide-growth-analysis

### RBC Capital Bullish on AbbVie: Initiates Coverage with Outperform Rating
2026-02-27 14:47:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
Full story: https://getfinancebrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.